Journal
VACCINE
Volume 28, Issue 4, Pages 1048-1055Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.10.123
Keywords
MLV; EHV-1; Abortigenic; EIV
Categories
Funding
- Equine Research at Cornell University
- Pfizer, Inc
Ask authors/readers for more resources
Vaccination is commonly used to control equine respiratory pathogens such as equine herpesvirus type 1 (EHV-1) and equine influenza virus (EIV). Here, we describe the generation and characterization of a recombinant EHV-1 modified live virus vaccine (MLV) based on a recent abortogenic EHV-1 strain, NY03 The immunogenicity and efficacy of the MLV was tested in horses in an EHV-1 vaccination/challenge experiment using the highly virulent neurovirulent EHV-1 strain OH03 Induction of a robust EHV-1-specific immune response was observed Upon challenge infection, vaccinated horses were partially protected against disease as demonstrated by a significant reduction in clinical signs, nasal shedding and viremia levels In addition, the NY03-based MLV was used to express the EIV H3 protein and immunogenicity was tested in horses. Expression of H3 was readily detected in NY03-H3-infected cells in vitro Vaccination of horses resulted in the induction of a robust serological Immune responses against two recent but genetically distinct EIV representatives. VA05 and NY-99, which were above the threshold predicted to be protective against development of clinical disease (C) 2009 Elsevier Ltd All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available